Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
325
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Ocular Therapeutix Inc market cap is $1.23B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Ocular Therapeutix Inc 52 week high is $16.44 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Ocular Therapeutix Inc 52 week low is $5.54 as of November 21, 2026.
Ocular Therapeutix Inc stock price today is $5.57.
Ocular Therapeutix Inc stock price yesterday was $5.86.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Ocular Therapeutix Inc's P/E ratio is -3.83.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Ocular Therapeutix Inc P/B ratio is 2.7776.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Ocular Therapeutix Inc 50-day moving average is $7.49.